GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Total Assets

AngioDynamics (AngioDynamics) Total Assets

: $324.8 Mil (As of Feb. 2024)
View and export this data going back to 2004. Start your Free Trial

AngioDynamics's Total Assets for the quarter that ended in Feb. 2024 was $324.8 Mil.

During the past 12 months, AngioDynamics's average Total Assets Growth Rate was -51.90% per year. During the past 3 years, the average Total Assets Growth Rate was -3.30% per year. During the past 5 years, the average Total Assets Growth Rate was -5.00% per year. During the past 10 years, the average Total Assets Growth Rate was -5.00% per year.

During the past 13 years, AngioDynamics's highest 3-Year average Total Assets Growth Rate was 116.50%. The lowest was -6.60%. And the median was 1.30%.

Total Assets is connected with ROA %. AngioDynamics's annualized ROA % for the quarter that ended in Feb. 2024 was -182.17%. Total Assets is also linked to Revenue through Asset Turnover. AngioDynamics's Asset Turnover for the quarter that ended in Feb. 2024 was 0.18.


AngioDynamics Total Assets Historical Data

The historical data trend for AngioDynamics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Total Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 836.44 594.21 561.44 552.75 532.64

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Total Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 542.85 532.64 493.95 499.62 324.84

AngioDynamics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

AngioDynamics's Total Assets for the fiscal year that ended in May. 2023 is calculated as

Total Assets=Total Equity (A: May. 2023 )+Total Liabilities (A: May. 2023 )
=378.296+154.341
=532.6

AngioDynamics's Total Assets for the quarter that ended in Feb. 2024 is calculated as

Total Assets=Total Equity (Q: Feb. 2024 )+Total Liabilities (Q: Feb. 2024 )
=218.698+106.144
=324.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AngioDynamics  (NAS:ANGO) Total Assets Explanation

Total Assets is connected with ROA %.

AngioDynamics's annualized ROA % for the quarter that ended in Feb. 2024 is

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=-750.944/( (499.623+324.842)/ 2 )
=-750.944/412.2325
=-182.17 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

AngioDynamics's Asset Turnover for the quarter that ended in Feb. 2024 is

Asset Turnover
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=75.182/( (499.623+324.842)/ 2 )
=75.182/412.2325
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

AngioDynamics Total Assets Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421